Insulet (PODD) is trading higher on May 1, 2026, as the market reacts to fresh visibility around the Omnipod 5 pod issue after the FDA updated its public recall communication on April 29, 2026. The FDA update said the action is classified as a Class I recall and included additional affected lots and updated information from the company, keeping the product-quality topic front and center for investors.

The recall communication centers on certain Omnipod 5 Pods where a manufacturing-related defect can lead to insulin leaking inside the pod rather than being delivered as intended. The FDA update notes Insulet sent an updated customer letter on April 10, 2026, expanding the list of affected lots and clarifying that the defect may not be detectable by users. Separately, a market update this week highlighted that Insulet has discussed confirmed serious adverse events tied to the issue and addressed confusion around broader injury counts appearing in device reports versus the company’s confirmed-event tally.

With the FDA’s April 29 update and follow-on market updates, investors are treating the news flow as incremental clarification rather than a brand-new escalation—potentially reducing uncertainty around scope, event counts, and financial impact versus worst-case fears. A second, near-term driver is positioning ahead of Insulet’s next earnings report on May 6, 2026 (after market close), when management is expected to revisit demand trends and any financial implications from the pod correction.

Attention now shifts to whether Insulet reiterates or adjusts 2026 guidance in light of replacement activity, operational remediation, and any downstream effects on Omnipod 5 adoption. Investors will also watch for any additional FDA updates, further lot expansions, or changes in the company’s stated view of the issue’s financial impact as the recall process continues.